Effects of Ziprasidone combined with Sodium valproate sustained-release tablets in treatment of patients with type Ⅰ bipolar disorders
Objective:To observe effects of Ziprasidone combined with Sodium valproate sustained-release tablets in treatment of patients with type Ⅰ bipolar disorders.Methods:A prospective study was conducted on 120 patients with type I bipolar disorders admitted to the hospital from February 2022 to June 2023.According to the random number table method,they were divided into control group and observation group,60 cases in each group.The control group was treated with Sodium valproate sustained-release tablets,while the observation group was treated with Ziprasidone on the basis of that of the control group.The clinical efficacy,the mania[the depression symptom[self-rating depression scale(SDS)]score,Young mania rating scale(YMRS)]score,the neurotransmitter index[5-hydroxytryptamine(5-HT),dopamine(DA)]levels before and after the treatment,and incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 95.00%(57/60),which was higher than 83.33%(50/60)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the scores of SDS and YMRS in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of 5-HT and DA in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Ziprasidone combined with Sodium valproate sustained-release tablets in the treatment of the patients with type I bipolar disorders can improve the total effective rate of treatment,reduce the SDS scores,the YMRS scores and the neurotransmitter index levels.Moreover,it is superior to simple Sodium valproate sustained-release tablets treatment.
Type IBipolar disorderZiprasidoneSodium valproate sustained-release tabletsManiaDepressive symptomsNeurotransmitter
NETL
NSTL
万方数据
